ReviewHematological oncology2021
Langerhans cell histiocytosis: Version 2021.
Review in Hematological oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 78 citations in OpenAlex.
- Vitamin D levels and skeletal quality of life in adult Langerhans cell histiocytosis.Endocrine connections · 2026Article
- Multifocal Langerhans cell histiocytosis involving the thyroid and several organs: a diagnostic dilemma.JCEM case reports · 2026Article
- A case of mixed histiocytosis (Erdheim-Chester disease and Langerhans cell histiocytosis) with STEAP3-associated anemia and type 4 hemochromatosis.Orphanet journal of rare diseases · 2026Article
- Adult Langerhans Cell Histiocytosis Presenting as an Isolated Rectal Polyp and Hematochezia.Cureus · 2026Article
- Langerhans Cell Histiocytosis Associated With Chronic Myeloid Leukemia: A Pediatric Case Report.Cancer reports (Hoboken, N.J.) · 2026Article
- Clinical and prognostic significance of initial fever in children with Langerhans cell histiocytosis.Translational pediatrics · 2026Article
- What to do to beat Langerhans cell histiocytosis of bone? A narrative review and case series of radiofrequency ablation.EFORT open reviews · 2026Review
- Alopecia as an atypical presentation of Langerhans cell histiocytosis in an adult male.JAAD case reports · 2026Article
- The Challenge of Differentiating Mixed Histiocytosis: A Case Report.Case reports in hematology · 2026Article
- Cutaneous Rosai-Dorfman disease involving the left ear responsive to systemic glucocorticoid: a case report.Frontiers in medicine · 2026Article
- Bilateral temporal skull xanthoma characterized as a Langerhans cell histiocytosis: a case report.Journal of medical case reports · 2025Article
- Efficacy and safety of dabrafenib-targeted therapy for pediatric langerhans cell histiocytosis: a systematic review and meta-analysis.Translational pediatrics · 2025Article
- First Report of the Coexistence of Langerhans Cell Histiocytosis and Epithelioid Hemangioma of the Larynx.Turkish archives of otorhinolaryngology · 2025Article
- High CCR6 expression increases the risk of pediatric Langerhans cell histiocytosis.Blood science (Baltimore, Md.) · 2025Article
- A rash not to miss: Langerhans cell histiocytosis.Paediatrics & child health · 2025Article
- Extracorporeal membrane oxygenation in the treatment of critical Pneumocystis jirovecii pneumonia in a child with Langerhans cell histiocytosis: a case report and literature review.BMC infectious diseases · 2025Review
- Adult-onset Langerhans cell histiocytosis with multisystem involvement: A rare case report.Radiology case reports · 2025Article
- Pruritic Maculopapular Eruption of a 4-month-old Baby: A Quiz.Acta dermato-venereologica · 2025Article
- Adult onset multisystem Langerhans cell histiocytosis initially presenting with arginine vasopressin deficiency: a case report.Frontiers in medicine · 2025Article
- The Molecular Pathology of Blood Cancer: A Comprehensive Review of Chromosome and Genetic Abnormalities and Their Clinical Utility.British journal of biomedical science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Children with Langerhnans cell histiocytosis (LCH) develop granulomatous lesions with characteristic clonal CD207+ dendritic cells that can arise as single lesions or life-threatening disseminated disease. Despite the wide range of clinical presentations, LCH lesions are histologically indistinguishable based on severity of disease, and uncertain classification as an immune versus neoplastic disorder has historically challenged the development of optimal clinical strategies for patients with LCH. Recently, activating somatic mutations in MAPK pathway genes, most notably BRAFV600E, have been discovered in almost all cases of LCH. Further, the stage of myeloid differentiation in which the mutation arises defines the extent of disease and risk of developing LCH-associated neurodegeneration. MAPK activation in LCH precursor cells drives myeloid differentiation, inhibits migration, and inhibits apoptosis, resulting in accumulation of resilient pathologic dendritic cells that recruit and activate T cells. Recurrent somatic mutations in MAPK pathway genes have also been identified in related histiocytic disorders: juvenile xanthogranuloma, Erdheim-Chester disease, and Rosai-Dorfman disease. New insights into pathogenesis support reclassification of these conditions as a myeloid neoplastic disorders. Continued research will uncover opportunities to identify novel targets and inform personalized therapeutic strategies based on cell of origin, somatic mutation, inherited risk factors, and residual disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.